Want to see SLXN full AI Analyst Report?
SLXN Stock Chart & Stats
$2.12
-$0.10(-4.76%)
At close: 4:00 PM EST
$2.12
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$2.30 - $223.60
Previous CloseN/A
Volume52.80K
Average Volume (3M)50.14K
Market Cap
$2.75M
Enterprise Value-$761.91K
Total Cash (Recent Filing)$2.41M
Total Debt (Recent Filing)$436.00K
Price to Earnings (P/E)<0.1
Beta0.29
Next Earnings
Aug 18, 2026EPS Estimate
-21.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)49.40
Shares Outstanding1,063,117
10 Day Avg. Volume60,134
30 Day Avg. Volume50,136
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit126.99
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$6.00Price Target Upside183.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-49.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory / Clinical ProgressSecuring regulatory approvals and submitting an EU Clinical Trial Application materially reduces execution risk for SIL204 over the next several months. This advances the program toward meaningful clinical readouts, improves the company’s ability to attract partners or grants, and increases the likelihood of milestone-driven financing or collaborations as the Phase 2/3 program begins.
Manufacturing / CMC ReadinessStarting GMP production with a major CDMO demonstrates CMC de-risking and operational readiness to supply a Phase 2/3 safety run-in and early cohorts. Reliable clinical supply is a durable enabler for timely dosing, reduces regulatory/commercial friction, and strengthens negotiations with potential partners or licensors by showing tangible manufacturing capability.
Supportive Preclinical DataPositive translational immuno-oncology data showing increased tumor MHC-I after SIL204 treatment provides a mechanistic rationale for combination strategies with checkpoint inhibitors. That scientific signal enhances the program’s clinical hypothesis and broadens potential indication and partner interest, supporting longer-term development value beyond single-agent activity.
Bears Say
No Revenue & High BurnThe company remains pre-revenue with persistent negative operating and free cash flow of about $12M TTM, creating ongoing reliance on external capital. This structural cash burn constrains runway, forces prioritization of programs, and increases execution risk over the next 2–6 months if additional funding or milestones are not secured.
Thin Equity Cushion / Leverage SensitivityAlthough absolute debt is modest, equity has only a small cushion after recent recapitalization, producing a high debt-to-equity ratio and financial sensitivity. A thin balance sheet reduces flexibility to absorb trial delays or unexpected costs, weakens bargaining power in partner deals, and increases the likelihood of dilutive financings if milestones slip.
Ongoing Capital Actions / Dilution RiskRecent shareholder approval to raise authorized share capital and implement a reverse split signals structural efforts to preserve listing status and enable future financings. While supporting access to capital, these corporate actions also create an ongoing dilution/overhang dynamic and highlight dependence on equity markets, which can limit strategic optionality and shareholder alignment.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $2.30 and its highest was $223.60 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $2.75M.
When is Silexion Therapeutics’s upcoming earnings report date?
Silexion Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 35 days.
How were Silexion Therapeutics’s earnings last quarter?
Silexion Therapeutics released its earnings results on May 18, 2026. The company reported -$8.5 earnings per share for the quarter, beating the consensus estimate of -$12.9 by $4.4.
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Undervalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate is -21.2.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 1,063,117 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Silexion Therapeutics reported an EPS of -$8.5 in its last earnings report, beating expectations of -$12.9. Following the earnings report the stock price went down -5.363%.
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Silexion Therapeutics
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
SLXN Stock 12 Month Forecast
Average Price Target
$6.00
▲(183.02% Upside)
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---